This inventor holds 2 USPTO granted patents. Top assignee: University of Missouri. Active years: 2019-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019-2022
Title: Innovations in Prostate Cancer Treatment by Wei Jin
Introduction
Wei Jin is an accomplished inventor based in Kansas City, MO (US), known for his significant contributions to the field of cancer research. He holds 2 patents that focus on innovative approaches to prostate cancer treatment. His work is primarily associated with the University of Missouri, where he collaborates with other researchers to advance medical science.
Latest Patents
Wei Jin's latest patents revolve around the discovery of novel prostate-specific membrane antigen (PSMA) targeting peptides. These peptides were identified through a novel combinatorial biopanning method. One of the notable peptides discovered is GTIQPYPFSWGY, also referred to as GTI. This peptide exhibits high binding affinity and selectivity to PSMA and PSMA-positive prostate cancer cells. Research has shown that GTI can mediate the internalization of the apoptotic KLA peptide into PSMA-positive LNCaP cells, leading to cell death. Furthermore, a FAM-labeled GTI peptide demonstrates high and specific tumor uptake in nude mice bearing human prostate cancer xenografts. This indicates that the GTI peptide can be utilized as a PSMA-specific ligand for both prostate cancer diagnosis and targeted drug delivery.
Career Highlights
Throughout his career, Wei Jin has focused on developing innovative solutions for cancer treatment. His research has led to significant advancements in understanding how specific peptides can target cancer cells effectively. His work has the potential to improve diagnostic methods and therapeutic strategies for prostate cancer patients.
Collaborations
Wei Jin collaborates with Kun Cheng, a fellow researcher at the University of Missouri. Together, they work on projects that aim to enhance the efficacy of cancer treatments through innovative peptide technologies.
Conclusion
Wei Jin's contributions to the field of prostate cancer research highlight the importance of innovation in medical science. His discoveries in PSMA-targeting peptides pave the way for improved diagnostic and therapeutic options for patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile